Copyright
©The Author(s) 2022.
World J Diabetes. Nov 15, 2022; 13(11): 962-971
Published online Nov 15, 2022. doi: 10.4239/wjd.v13.i11.962
Published online Nov 15, 2022. doi: 10.4239/wjd.v13.i11.962
Stage | Defensin | Activation |
Inflammation | HNP1-2, HBD1-3[28] | Recruitment of leukocytes |
HNP1-4[29] | Secretion of inflammatory cytokines like IL-8 | |
HBD2-4[32] | Activation of the p38 and ERK1/2 MAPK pathways | |
HNP1, HBD2[35] | Activation of the p42/44 MAPK pathways | |
HBD2, HBD3[36] | Down-regulate the TIR, TRAF-6, NF-κB of TLR signaling pathways | |
HBD3[37] | Induce M2 macrophage differentiation | |
Re-epithelialization | HNP1[43], HBD2-3[42] | Induce keratinocyte migration and proliferation |
HBD1[44] | Protect keratinocytes from apoptosis | |
Collagen synthesis | HNP1[45] | Enhance extracellular matrix deposition |
HBD3[20,37] | Increase the expression of MMP-2, and down-regulate the expression of MMP-9 | |
Fibroplasia | HNP1[45], HBD2[46] | Promote the proliferation and activation of fibroblasts |
Angiogenesis | HNP1[51], HBD2[52], HBD3[53] | Induce VEGF |
HBD1-4[54] | Induce angiogenin | |
HNPs[55] | Inhibit adhesion and migration of endothelial cell | |
Nerve reconstruction | HNP1[40] | Promote the recovery of neurological function |
HBD3[57] | Modulate the expression of nerve elongation factors | |
Antimicrobial activity | HNP1-4, HBD1-4[61] | Exhibit a broad range of antimicrobial properties |
HBD2[60] | Reduce biofilm formation | |
HNP1-3[62] | Neutralize bacterial toxins | |
HNP1, HBD1, HBD3[63] | Show synergy of action with antibiotics |
- Citation: Tan ZX, Tao R, Li SC, Shen BZ, Meng LX, Zhu ZY. Role of defensins in diabetic wound healing. World J Diabetes 2022; 13(11): 962-971
- URL: https://www.wjgnet.com/1948-9358/full/v13/i11/962.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i11.962